EANS-News: Intercell AG / Vivalis SA shareholders approved the proposed merger of equals to create Valneva SE

Wien (euro adhoc) -

Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.

Company Information

Nantes (France), Vienna (Austria), March 7, 2013 - Intercell
AG (VSE: ICLL) and Vivalis SA (NYSE Euronext: VLS) today announced that the Extraordinary General Meeting of both companies approved the proposed merger of equals between Intercell AG and Vivalis SA to create Valneva SE.

In today's Extraordinary Shareholders' Meeting of Vivalis held in Nantes, France, all resolutions were approved by its shareholders. A majority of 99.1% of the represented share capital voted in favor of the merger to create Valneva SE, a biotech leader in vaccines and antibodies. A total of approximately 70% of the outstanding share capital of Vivalis SA was represented in the shareholders meeting.

As previously announced, Intercell's shareholder approved the proposed merger with Vivalis SA with a majority of 97.4% of the represented share capital.

Following the approvals of the both shareholders the merger is now only subject to completion of certain administrative steps and is expected to close in May 2013. Subject to the approval of the French market authorities, Valneva SE will launch a EUR 40 million capital increase shortly after the completion of the Merger.

Thomas Lingelbach, future President and Chief Executive Officer of Valneva and Franck Grimaud, future President and Chief Business Officer commented: "We are excited about the broad approval of the merger by our shareholders and are now heading towards closing in May 2013. Valneva will be a European biotech leader in vaccines and antibodies with complementing talents and capabilities, a broad portfolio of product candidates, diversified revenues and enhanced financial strength to fund its future growth."

end of announcement euro adhoc

company: Intercell AG Campus Vienna Biocenter 3 A-1030 Wien phone: +43 1 20620-0 FAX: +43 1 20620-800 mail: investors@intercell.com WWW: www.intercell.com sector: Biotechnology ISIN: AT0000612601 indexes: ATX Prime

stockmarkets: official market: Wien
language: English

Digital press kit: http://www.ots.at/pressemappe/116/aom

Rückfragen & Kontakt:

Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | CNE0006